





For example:

- When compared with control group, tiotropium was associated with a significant delay in time to first exacerbation (16.7 months vs. 12.5 months) and a 14% reduction in the probability of exacerbation leading to hospitalisation (HR: 0.86; P=0.002).<sup>6</sup>
- In a head-to-head study, tiotropium significantly increased the time to first exacerbation compared with the LABA salmeterol by 42 days (187 vs. 145 to a 17% reduction in risk (HR: 0.83; P<0.001).<sup>7</sup>
- When compared with indacaterol, tiotropium afforded greater clinical protection from exacerbations, with a 29% lower rate of moderate-